- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Non-Conventional Radiotherapy May Reduce Dry Mouth
Parotid-sparing intensity-modulated radiotherapy (IMRT) is less likely than conventional radiotherapy to result in dry mouth in patients treated for head and neck cancer, according to research published online Jan. 13 in The Lancet Oncology.
THURSDAY, Jan. 13 (HealthDay News) -- Parotid-sparing intensity-modulated radiotherapy (IMRT) is less likely than conventional radiotherapy to result in dry mouth in patients treated for head and neck cancer, according to research published online Jan. 13 in The Lancet Oncology.
Christopher M. Nutting, M.D., of the Royal Marsden Hospitals NHS Foundation Trust in London, and colleagues randomized 94 patients with pharyngeal squamous-cell carcinoma to IMRT or conventional radiotherapy to test their hypothesis that IMRT reduces the incidence of severe xerostomia.
The researchers found that, of the patients available for analysis at 12 months, 38 percent of those in the IMRT group reported grade 2 or worse xerostomia, compared with 74 percent of the conventional radiotherapy group. By 24 months, 29 percent of the IMRT group and 83 percent of the conventional radiotherapy group reported grade 2 or worse xerostomia. The IMRT group had a higher prevalence of grade 2 or worse fatigue, but there were no significant differences between the two groups in terms of non-xerostomia late toxicities, locoregional control, or overall survival.
"Sparing the parotid glands with IMRT significantly reduces the incidence of xerostomia and leads to recovery of saliva secretion and improvements in associated quality of life, and thus strongly supports a role for IMRT in squamous-cell carcinoma of the head and neck," the authors write.
AbstractFull Text (subscription or payment may be required)
Copyright © 2011 HealthDay. All rights reserved.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
